Novartis on course to set new highs
20/02/24 -"Considering the strong operational performance and a meaningful progress for the late-stage pipeline in recent years, we have revised upwards our NAV estimates by c.10%."
Pages
65
Language
English
Published on
20/02/24
You may also be interested by these reports :
19/08/26
The Q2 sales were ahead of expectations, though profitability was in line with consensus. Strong growth for the migraine drug Vyepti, ...
18/08/26
The H1 results exceeded expectations, backed by strong growth in Bimzelx and other key products. Consequently, the management revised the full-year ...
17/08/26
The Q2/H1 results surpassed expectations, again driven by the Biosimilars growth engine, as Generics posted muted growth. Also, the management ...
14/08/26
The Q2 results exceeded consensus estimates, driven by a healthy showing from Crop Science, whereas the growth for the other two businesses was ...